Vimian Group AB (publ) engages in the animal health business worldwide. It operates through Specialty Pharma, MedTech, Diagnostics, and Veterinary Services segments. The company offers proprietary diagnostics, prescription, and non-prescription treatments for preventive care and treatment of chronic conditions for companion animals under the Nextmune brand name; and molecular and immunodiagnostic solutions that are used by laboratories for veterinary specific applications with a focus on livestock and companion animal health markets under the Indical Bioscience brand name. It also provides procurement and tech-driven operations, such as online marketing, and education and HR, as well as a community for veterinary clinics through a membership-based platform under the VetFamily brand name; and orthopedic implants for veterinarians and universities under the Movora brand name. Vimian Group AB (publ) was incorporated in 2020 and is headquartered in Stockholm, Sweden.
Metrics to compare | VIMIAN | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipVIMIANPeersSector | |
---|---|---|---|---|
P/E Ratio | 65.1x | 18.6x | −0.5x | |
PEG Ratio | 0.68 | 0.12 | 0.00 | |
Price/Book | 2.2x | 2.7x | 2.6x | |
Price / LTM Sales | 3.7x | 12.9x | 3.3x | |
Upside (Analyst Target) | 25.7% | 40.2% | 41.6% | |
Fair Value Upside | Unlock | 21.1% | 5.9% | Unlock |